+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Disorders Market in United States, Forecast to 2022

  • ID: 4900518
  • Report
  • December 2019
  • Region: Global
  • 139 Pages
  • Frost & Sullivan
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
Huge Gaps and Unmet Needs Across the Care Continuum Provide Opportunities for Companies to Realize Market Potential

FEATURED COMPANIES

  • Apax Medical
  • Royal Philips
  • MORE

Global resource constraints on health systems are driving a shift to value-based healthcare to reduce cost, increase access, and improve outcomes. In the United States, resource constraints affect more than 20% of the population. The number of respiratory therapists is declining at a rate of 4% to 7%, while the demand for respiratory specialists will increase by 35% by 2020. The role of respiratory therapists is critical in keeping patients out of emergency or hospital care. In the United States, nearly 15% of all primary care visits, or more than 125 million patient visits alone, are for respiratory-related conditions. Within respiratory diseases, 4 conditions primarily contribute to the high burden of respiratory disease. These include asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infections (RTI), and lung cancer. More than 100 million people are affected by the respiratory disease in the United States, which highlights the staggering magnitude of the burden of respiratory /lung disease. The demand-supply gap for resources is expected to widen further with the increase in incidence rates of respiratory diseases.

Though respiratory disease is one of the leading causes of morbidity and mortality among non-communicable diseases, most major respiratory conditions are preventable. Much of the respiratory conditions can be mitigated by improved screening and early diagnosis of patients/public, especially in the smoking population. Government agencies and respiratory associations are strategizing measures to reduce the burden of respiratory and sleep-related disorders to have a profound effect on the respiratory health for patients, reduce economic costs, and improve the quality of life for people. Screening/diagnosis and monitoring account for only 16% of the total spending on respiratory care. A major portion, or more than 60%, of healthcare spending, is still in treatment. Investment trends show that patient medication adherence and monitoring remains the most attractive domain within respiratory care. However, little emphasis was laid on diagnosis/screening, which remains one of the primary unmet needs in the respiratory care continuum. Screening and patient medication adherence remain key market growth opportunities for OEMs within the respiratory care industry.

This research service provides an overview of the unmet needs and gaps in the respiratory disease sector and provides details on investment/funding in the respiratory sector. The unique value of this study is that it provides insights, challenges, and unmet needs for 10 major respiratory and sleep apnea conditions. This research also identifies growth opportunities by care continuum and technologies within sleep and respiratory care.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apax Medical
  • Royal Philips
  • MORE

1. Executive Summary

  • Current Spending on Respiratory Care in the United States
  • Respiratory Care Spending by Care Continuum
  • Investment Landscape in Sleep and Respiratory Disease Sector by Clinical Applications
  • Focus of OEMs in Sleep and Respiratory Disorders
  • Spending on Sleep and Respiratory Disorders - Summary

2. Introduction to Respiratory Care Diseases

  • Trends Shaping the Sleep and Respiratory Care Industry
  • Sleep and Respiratory Disease Burden in the United States
  • Spending on Sleep and Respiratory Disorders - Summary

3. Lung Cancer - Market Landscape Assessment

  • Overview of Lung Cancer - Disease Burden and Spending by Care Continuum
  • Lung Cancer - Unmet Needs and Opportunity Analysis
  • Scenario Analysis - Lung Cancer Screening Population Analysis

4. COPD - Market Landscape Assessment

  • Overview of COPD - Disease Burden and Spending by Care Continuum
  • COPD - Unmet Needs and Opportunity Analysis
  • Scenario Analysis - COPD Medication Adherence Analysis

5. Cystic Fibrosis - Market Landscape Assessment

  • Overview of Cystic Fibrosis - Disease Burden and Spending by Care Continuum
  • Cystic Fibrosis - Unmet Needs and Opportunity Analysis

6. Asthma - Market Landscape Assessment

  • Overview of Asthma - Disease Burden and Spending by Care Continuum
  • Asthma - Unmet Needs and Opportunity Analysis
  • Scenario Analysis - Asthma Medication Adherence Analysis

7. Pulmonary Fibrosis - Market Landscape Assessment

  • Overview of Pulmonary Fibrosis - Disease Burden and Spending by Care Continuum
  • Pulmonary Fibrosis - Unmet Needs and Opportunity Analysis

8. PE - Market Landscape Assessment

  • Overview of PE - Disease Burden and Spending by Care Continuum
  • PE - Unmet Needs and Opportunity Analysis
  • Scenario Analysis - PE Medication Adherence Analysis

9. RTI - Market Landscape Assessment

  • Overview of RTI - Disease Burden and Spending by Care Continuum
  • RTI - Unmet Needs and Opportunity Analysis

10. Chronic Bronchitis - Market Landscape Assessment

  • Overview of Chronic Bronchitis - Disease Burden and Spending by Care Continuum
  • Chronic Bronchitis - Unmet Needs and Opportunity Analysis

11. Sleep Apnea - Market Landscape Assessment

  • Overview of Sleep Apnea - Disease Burden and Spending by Care Continuum
  • Sleep Apnea - Unmet Needs and Opportunity Analysis
  • Scenario Analysis - Sleep Apnea Treatment Adherence Analysis

12. Pneumonia - Market Landscape Assessment

  • Overview of Pneumonia - Disease Burden and Spending by Care Continuum
  • Pneumonia - Unmet Needs and Opportunity Analysis

13. Pleural Effusion - Market Landscape Assessment

  • Overview of Pleural Effusion - Disease Burden and Spending by Care Continuum
  • Pleural Effusion - Unmet Needs and Opportunity Analysis

14. Infrastructure, Government/Association Plans, and Strategies for Respiratory Care

  • Resource and Infrastructure Analysis in the United States
  • Programs and Long-term Plans by Respiratory Disease Types

15. New Entrants and Start-ups Disrupting the Respiratory Ecosystem

  • Top-level Snapshot of Funding by Care Continuum
  • Top-level Snapshot of Funding by Technologies
  • Focus of OEMs in Sleep and Respiratory Disorders
  • Select List of Start-up Companies
  • Game Changers or Start-ups Disrupting Respiratory Industry - List of Companies
  • Current and Recommended Business Models

16. Innovative Technologies/Solutions

  • Technology 1 - Respiratory Airway Clearance Vest
  • Technology 2 - Digital Capnography (Tidal Breathing CO2) Diagnostic and Monitoring Device for Home Care
  • Technology 3 - Smartphone-enabled or Connected Spirometers
  • Technology 4 - Continuous Respiratory Rate Monitoring
  • Technology 5 - Implantable Nerve Stimulator for Sleep Apnea
  • Technology 6 - Oral Appliances for Sleep Apnea
  • Technology 7 - Miniaturized CPAP
  • Technology 8 - Smart Inhalers/Sensors
  • Technology 9 - Respiratory Dialysis System (ECCO₂R Therapy)
  • Technology 10 - Breath Analyzer for Non-invasive Lung Cancer Screening
  • Technology 11 - AI to Process Patients’ Medical Imaging
  • Technology 12 - Patient Management Apps
  • Technology 13 - Wearable Devices
  • Technology 14 - Lung Perfusion System
  • Technology 15 - Assistive Robots
  • Product/Technology Pipeline in Sensor-based Technologies in Respiratory and Sleep Diseases, 2018

17. Analysis of Mergers, Acquisitions and Partnerships

  • Analysis of M&A Deals in the Global Respiratory Device Industry
  • Mergers and Acquisitions
  • Royal Philips - M&A Strategy
  • Apax Medical - M&A Strategy
  • Key M&As Discussion
  • Select Partnerships and Collaborations in Respiratory and Sleep Disorders

18. Growth Opportunities and Companies to Action

  • Shifting Care Delivery in Sleep and Respiratory Industry
  • Growth Opportunity by Technologies in the Sleep and Respiratory Industry
  • Select Sleep and Respiratory Technologies Impact by Care Settings
  • Growth Opportunity Areas for Companies
  • Growth Opportunity - Collaborations and Partnerships Among Vendors
  • Strategic Imperatives
  • Future Trends in the Sleep and Respiratory Care Industry
  • Growth Opportunities in Sleep and Respiratory Sector by Services/Solutions

19. Analyst Perspective and Conclusion

  • Analyst Perspective
  • 3 Big Predictions
  • Strategic Imperative and Growth Opportunities for Companies
  • Legal Disclaimer

20. Appendix

  • List of Exhibits
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Apax Medical
  • Royal Philips
Note: Product cover images may vary from those shown
Adroll
adroll